First Horizon Advisors, Inc. Bei Gene, Ltd. Transaction History

First Horizon Advisors, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 02, 2022	BUY	$121.11 - $216.05 $242 - $432	2 Added 10.53%	21 $3,000
Q1 2022 May 10, 2022	SELL	$146.52 - $269.56 $12,893 - $23,721	-88 Reduced 82.24%	19 $4,000
Q4 2021 Feb 09, 2022	SELL	$248.56 - $389.34 $5,468 - $8,565	-22 Reduced 17.05%	107 $28,000
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $86,361 - $139,486	-346 Reduced 72.84%	129 $46,000
Q3 2021 Nov 09, 2021	BUY	$249.6 - $403.14 $86,361 - $139,486	346 Added 268.22%	475 $172,000
Q3 2018 Nov 05, 2018	BUY	$152.62 - $189.66 $19,687 - $24,466	129 New	129 $0

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.